AMRX - Amneal Pharmaceuticals, Inc.
13.02
-0.240 -1.843%
Share volume: 1,048,886
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.15%
PREVIOUS CLOSE
CHG
CHG%
$13.26
-0.24
-0.02%
View ratios
| Fiscal Date | 12-31-2025 | |
|---|---|---|
| Fiscal Quarter | Q4 2025 | |
| Report Date | 02-27-2026 | |
| Total revenue | 814.319 M | |
| Cost of revenue | 517.129 M | |
| Gross profit | 297.190 M | |
| Operating expenses | 182.688 M | |
| Selling general and admin | 146.458 M | |
| Research and development | 36.230 M | |
| Total expenses | 185.157 M | |
| Operating income | 112.033 M | |
| Ebit | 111.472 M | |
| Pretax income | 55.235 M | |
| Income tax | 5.662 M | |
| Net income basic | 0.000 | |
| Net income | 49.573 M | |